|Address||B1, Center for Medical Innovation, Seoul National University Hospital, 71 Daehak-ro, Jongno-gu, Seoul, 03082, Korea|
QuantaMatrix provides IVD products with a mission to solve the global challenges of antimicrobial resistance by earlier and faster diagnosis. Its flagship product, dRAST, is developed by integrating the core technologies such as microfluidics, time-lapse imaging, and big-data analytics, and it is adopted by top-tier medical centers and laboratories around the world to revolutionize susceptibility testing process. Established in 2010 as a spin off from Biophotonics and Nano Engineering Lab (BiNEL) at Seoul National University, QuantaMatrix is now operating in Korea and Europe. In Europe, its dedicated business partners have distributed dRAST all over the regions since 2019, and the company is now expanding its business into North America and Asia as well. For further information, please visit the corporate website (quantamatrix.com) or YouTube Channel (QuantaMatrix Media).
dRAST provides MIC-based phenotypic antimicrobial susceptibility testing directly from positive blood culture in as low as 5-7 hours; reducing time to results by up to 2 days compared to conventional method. The rapid results allow for earlier optimization of antimicrobials in critically-ill patients with bloodstream infections and sepsis. (1) Compliant with CLSI and EUCAST guidelines (2) Easy start with no McFarland required, no sample prep (3) 2 panels available: 1 Gram Positive Panel and 1 Gram Negative Panel
QDST provides a rapid, phenotypic drug susceptibility testing for tuberculosis. The system performs susceptibility test results for 15 drugs, including first and second line agents, in 7 days. This can allow laboratories to shorten turnaround time by 3 to 5 weeks compared to the conventional test methods. (1) 4 primary and 11 secondary anti-TB drugs for drug susceptibility testing (2) LNZ and Cs for patients with resistance to quinolones (3) Multi-concentrations for INH, RIF, EMB, and Cs.